						0017110	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
FORM P						SERIAL NO.		101	538196	
INFORM	IAT	ION	DISCLOSURE ST	FATEMENT		FILING DATE				
						APPLICANT		Peckham	Peckham et al.	
						GROUP				
						EXAMINER				
						ATTORNEY DOCKET NO. PU4964USw			JSw	
	_	_		U.S. I	PATENT D	OCUMENTS				
	\neg								Filing Date	
Examine	r		Patent	Issue Date		Name	Class	Subclass	If Appropriate	
Initials			Number							
	T									
	\dashv	_		1	 					
	\dashv		+	1	1					
	\dashv		+	 	+		 			
-	-+		+				1			
	\neg	_	+	+	+		 			
	-+	_			+		 			
					Continue on p					
	_					F DOCUMENTS				
	_		T		NPALENI	DOCUMENTS	т		Translation	
			Document	Publication	Ι.,	~ .4	GL	Cubalasa	Yes No	
/D O I	-		Number	Date		Country	Class	Subclass		
/D.G./	_		I. WO00/39125	7/6/2000	PCT					
/D.G./	_	2	2. WO0038680	7/6/2000	PCT					
	_						\vdash			
					T		L			
	\Box		T		T					
	コ	_	\top						3	
	\neg									
	\neg	_								
	┪	_			1		† †		—	
	┪	_		1	1		 			
	_				Continue on p	nage				
	_	_	OTHER DOCLE			Title, Journal-Da	te Page Num	her, Etc.)		
		3. 1							activity	
/D.G./		7.	FINKE et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-'N-(methyl)-N-(phenylsulfonyl)amino)-4-(piperidin-1-yl) butanes,							
10.0.		- 1	Bioorganic and Medicinal Chemistry Letters 11(2):265-270 (2001).							
	-	4. FINKE et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed								
/D.G.	ľ	pharmacophore model for 1-(N-(methyl)-N-(phenylsulfonyl)amino)-2-(phenyl)-4-(4-(substituted)pipe								
	l		pharmacophore model for 1-(N-(methyl)-N-(phenylsulfonyl)amino)-2-(phenyl)-4-(4-(substituted)piperidin-1-yl)butanes, Bioorganic and Medicinal Chemistry Letters 11(18):2469-2473 (2001).							
	⊢	5.	FINKE et al., Anta	ists of the bu	CCP5	Dellers I 1(10).27	/ Lagente Da	J. → A: cymthecis	and etructure-	
		۱.	activity relationship							
/D.G./	l	- 1								
			(benzyloxycarbonyl)amino)piperidin-1-yl)butanes, Bioorganic and Medicinal Chemistry Letters 11:2475-2479 (2001). DORN et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial							
	-	-								
	ŀ	0.	 DORN et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initia structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, Bioorganic and Medicinal 							
/D.G./	1	- 1				enyl-4-(piperium-	1-yl)ouanes, o	loorgame and	1 Medicinai	
	├—	- -+	Chemistry Letter 11(2):259-264 (2001).							
/D.G./	l	7. MAEDA et al., The current status of the challenges in, the development of CCR5 inhibitors as there								
10.000	⊢		infection, Current Opinion in Pharmacology 4(5):447-452 (2004). KUMAR et al., Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5)							
	1	8.								
/D.G./	1	- 1	with Ritonavir in Rats and Monkeys: Role of CYP3A and P-glycoprotein, J. of Pharmacology and							
	⊢	-	Experimental therapeutics 304(3):1161-1171 (2003).							
/D.G./	•	9.	BONNAUD et al., 1-Aryl-2-(aminomethyl))cyclopropanecarboxylic Acid Derivatives. A New Series of Potential Antidepressants, J. Med. Chem 30:318-325 (1987).							
	┞	-	Potential Antidepre	ssants, J. Med. C	hem 30:316	-325 (1987).				
	<u> </u>	_								
	L									
Continue on page										
EXAMIN	ER		/David Ga	allie/			DATE	CONSIDERE		
								11/18/		
FXAMIN	FP.	Init	ial if citation consid-	ered, whether or	not citation	is in conformance	with MPEP & 6	i09: Draw line	e through	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.